Skleo Health, a healthtech company based in Düsseldorf, Germany, has secured €3 million in new funding to expand their network of eye screenings nationwide. The initiative aims to address the significant issue of preventable blindness by leveraging advanced AI technology and collaboration with various partners. With this recent investment, the company seeks to make substantial strides in how eye health is approached in Germany, serving a large segment of the population that suffers from treatable eye conditions.
The challenge of preventable blindness isn’t a recent concern for Germany. In recent years, similar initiatives aimed at improving eye health have highlighted the gap between demand and service provision, especially concerning wait times for specialist appointments within the healthcare system. These past efforts, however, did not always establish strong partnerships or the use of technology at the level Skleo Health now proposes. Thus, Skleo Health’s ambitious expansion could play a crucial role in creating more efficient and timely access to eye care.
How Can Skleo Health Make a Difference?
Skleo Health proposes to address the critical issue of late diagnosis by incorporating their CE-certified AI system into preventive screenings at accessible locations such as opticians, pharmacies, and retail stores. This innovative approach ensures screenings are time-efficient, taking only six minutes, and offers a reliable two-step verification procedure involving AI and licensed ophthalmologists. This setup is envisioned to mitigate the extensive delays patients generally face in specialized eye care access.
Who is Behind Skleo Health?
The founders of Skleo Health emerged from a deep-rooted collaboration developed during a residency with Antler. The founding team consists of Dr. Steffen E. Künzel, a seasoned ophthalmologist, Fabien Vogl, an engineer with substantial healthcare experience, and Dr. Alex Hein, a mathematician and economist. Their diverse backgrounds contribute to the robust digital platform intended to streamline eye screening and facilitate early intervention.
The capital from this funding round will fundamentally bolster Skleo Health’s capacity, aiming to facilitate 30,000 screenings monthly and establish a robust network connecting patients with eye care specialists. The strategic partnership with Sanoptis will be pivotal, as it extends the geographic reach and efficacy of the newly scaled operations.
Dr. Steffen E. Künzel remarked, noting the critical nature of timely diagnosis, “Every day in the clinic, I witnessed the profound impact of late-stage diagnosis, where treatment options are often limited.”
The company’s emphasis is shifting healthcare paradigms from reactive to preventive services, hoping to alleviate the burden on the healthcare system while offering timely interventions.
Sanoptis, a major ophthalmic services provider, underlines the transformative potential of Skleo Health in managing preventive eye care. They celebrate incorporating innovative AI into a wide network, which is set to enhance diagnostic accuracy while increasing accessibility for patients.
Emerging as a notable player backed by investors like Antler, Skleo Health integrates their high-level medical insight with an evolving technological platform. This synergy allows them to respond adeptly to ongoing challenges within the eye care sector, leveraging seasoned experience to address current system deficiencies and delivering a proactive healthcare model.
As an endeavor rooted in combining cutting-edge technology and expansive interdisciplinary cooperation, Skleo Health’s trajectory aims to make preventive health measures a consistent standard of care across Germany. Regular screenings supported by AI could significantly lower healthcare delays and ensure diseases are addressed long before they progress.
